Just days after going public, Jerini has succeeded in its quest to find a North American partner for its niche Phase III drug, by signing an exclusive licensing deal with Kos Life Sciences, a subsidiary of the US speciality pharma company, Kos Pharmaceuticals. The therapy in question is Jerini's proprietary compound, icatibant, a potent and specific peptidomimetic bradykinin (BK) B2 receptor antagonist for hereditary angio-oedema (HAE). While icatibant might not necessarily be the first therapy to receive approval for HAE in the US, there is undoubtedly still room for the drug to flourish in this as yet uncharted market, especially with Kos onside.